GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
Live video webcast on Tuesday, June 18th at 11:00 AM ET
View original post here:
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor Pitch Conference
Author Archives: admin
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential…
MIAMI, June 11, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for rare, life-threatening and chronic aging-related conditions, today announced the successful completion of an investigator meeting for ELPIS II, the on-going Phase 2b clinical trial evaluating Lomecel-B™ as a potential adjunct treatment for Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric congenital heart birth defect. The investigator meeting was organized to discuss the progress to date and operational implementation of the clinical trial, inviting the principal investigator and site staff from premiere infant and children’s treatment institutions across the country. ELPIS II is on track to complete enrollment by the end of 2024.
Here is the original post:
Longeveron® Announces Completion of Successful Investigator Meeting for On-going Phase 2b Clinical Trial Evaluating Lomecel-B™ as a Potential...
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA…
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results--SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced the successful completion of a Type-B meeting with the U.S. Food and Drug Administration (FDA) on next steps for the Biologics License Application (BLA) submission with its lead asset, CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD). Additionally, Deramiocel has been selected as the proposed International Nonproprietary Name (INN) for CAP-1002 by the World Health Organization.
Read more from the original source:
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA...
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
ISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.
See original here:
Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies…
MHSRS is America’s Foremost Annual Military Healthcare Conference MHSRS is America’s Foremost Annual Military Healthcare Conference
Originally posted here:
Origin Life Sciences Abstract Accepted for Presentation at 2024 Military Health System Research Symposium (MHSRS) Discussing Innovative Technologies...
IPSEN – Buy-back programme – Art 5 of MAR – Week 23 – 2024
Aggregated presentation by day and by market
Read more:
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Secretome profiles from SpaceX Inspiration4 mission show alterations in oxidative stress, brain homeostasis, and coagulation
The rest is here:
Seer Proteograph™ Provides Differentiated Insights into Spaceflight Proteomic Alterations for Precision Medicine and Biomarker Discovery
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on June 6, 2024, the Compensation & Management Development Committee of Rhythm’s Board of Directors granted inducement equity grants covering an aggregate of 56,080 shares of its common stock to ten new employees, consisting of inducement stock options to purchase an aggregate of 9,230 shares of common stock and inducement restricted stock units, or RSUs, covering an aggregate of 46,850 shares of its common stock.
Read the rest here:
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
WARREN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 million in financing. This formalizes the binding term sheet previously announced May 10, 2024.
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets
CLEVELAND, June 11, 2024 (GLOBE NEWSWIRE) -- SPR® Therapeutics, a leader in the use of peripheral nerve stimulation (PNS) to address different types of pain throughout the body, announced the publication of a review of prospective studies evaluating the impact on chronic pain following percutaneous PNS treatment. Published in Pain Management, the review identified studies evaluating PNS treatment for three primary treatment applications: low back pain, shoulder pain, and neuropathic pain. Studies included in the review all utilized treatment with short-term percutaneous PNS for up to 60 days with leads placed to target participants’ specific pain.
Continue reading here:
New Publication Reviewing Percutaneous PNS in the Management of Chronic Pain Highlights Consistent, Sustained Relief of Pain Across Multiple Targets